Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Fungus from The Last of Us Could Help Fight Cancer

The Last of Us, HBO’s videogame-inspired zombie TV epic, opened to rave reviews last month. This drama, led by Game of Thrones stars Pedro Pascal and Bella Ramsey, shows a post-apocalyptic world that has been ravaged by the corydceps fungus after the fungus adapts for survival in the human body. Scarily enough, the fungus from…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The Last of Us, HBO’s videogame-inspired zombie TV epic, opened to rave reviews last month. This drama, led by Game of Thrones stars Pedro Pascal and Bella Ramsey, shows a post-apocalyptic world that has been ravaged by the corydceps fungus after the fungus adapts for survival in the human body. Scarily enough, the fungus from The Last of Us is very, very real, and it’s turned many more casual eyes to the world of mycology. Should people give the cordyceps fungus the horror treatment, though?

Cordyceps’ claim to fame isn’t off base; some species of the fungus are known to infect insects and basically, turn them into zombies. Interest in the series has raised questions of whether a cordyceps-fueled pandemic can actually threaten humanity. Experts in the field of mycology say it is highly improbable and would require major genetic changes, which would probably develop over the course of millions of years.

Although the fungus may be terrifying for invertebrates, outside of The Last of Us’s lore, cordyceps is actually quite useful for humans. It is a widely used ingredient in traditional Chinese medicine, and recent research shows it may even have anti-cancerous properties. So as media consumers clamor for cordyceps content, how is the science community approaching research around the zombie fungus? Leslie Samuel, founder of Interactive Biology, a Master’s in Neurobiology holder, and an experienced science educator, breaks down some of the most recent research surrounding the fungus from The Last of Us.

Leslie’s Thoughts:

“In the field of mycology, which is the study of fungi, there’s been a lot of interest in the cordyceps fungus. That’s the same type of fungus that the show, The Last of Us, is based on. We know that certain species of that fungus can infect ants, turning them into zombies, and when they get infected, those ants will climb up a tree and bite into it, basically committing suicide as the fungus takes over their bodies and [causes] them to release more spores so that they can infect more ants. And the cycle continues like in The Last of Us, but with ants.

But there are also studies that show that certain species of the cordyceps fungus have potential anti-cancer effects. They’ve demonstrated that certain extracts from some species of the cordyceps fungus seems to inhibit the growth of liver cancer. And other studies suggest that there are specific substances in some species that inhibit the inflammatory response in certain immune system cells in mice. Now, there’s still a lot more research that needs to be done to confirm that these effects can actually help in therapies in the future. But this entire field of mycology is fascinating, with these fungi having both harmful and potentially life-saving properties.”

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Health systems are partnering up without changing who owns the hospital

Health systems are partnering up without changing who owns the hospital

Health systems are choosing alliances over mergers, per a July McDermott Will & Schulte analysis and four July deals tracked by Becker's Hospital Review. St. Christopher's, Nemours, Jefferson and Temple signed a nonbinding alliance letter; Palomar UC San Diego Health launched July 1. Ownership stays put; governance, purchasing and outpatient investment absorb the change.

  • 01In an alliance, the contract does the integrating that an org chart does in a merger: McDermott Will & Schulte says governance design, exclusivity, antitrust review, community commitments and exit rights all have to be settled before signing.
  • 02Purchasing is now explicitly on the table in at least one no-ownership deal, the St. Peter's Health and Billings Clinic-Logan Health talks in Montana, which means shared supply contracts can arrive without a change of control.

Sep 19, 2026

Telemedicine in eye care stops at the retinal scan unless imaging moves home

Telemedicine in eye care stops at the retinal scan unless imaging moves home

An Ophthalmology Times commentary by T.Y. Alvin Liu, Ferdinand Hui and Phillip Phan sorts eye patients into three telemedicine tiers by clinical need. Patients needing regular OCT scans benefit less unless a home device can send the image. Video tools already sit inside Epic and Cerner; the deciding purchase for retina clinics is the imaging device in the patient's living room.

  • 01The dividing line for eye telemedicine is imaging, not video: patients who need regular OCT scans benefit less from remote visits unless a device at home can send the scan, so a video license alone shifts few of those encounters.
  • 02The provider-side requirement, a HIPAA-compliant secured video platform, was already built into Epic and Cerner by 2020; the patient-side requirements (1.5 MB up and down bandwidth, a quiet private room, comfort with the technology) sit outside the health system's control and are the ones worth screening for at scheduling.
  • 03Self-administered home color fundus photography for tracking non-proliferative diabetic retinopathy was named as the nearer route into retina telemedicine; home OCT for wet AMD is the harder gate and the device to watch.

Sep 19, 2026

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Wolters Kluwer Health argues value-based care software is judged on whether customers hit incentive thresholds and avoid penalties. A Fierce Healthcare-reported survey it cites puts value-based care at a quarter or more of revenue for 30% of organizations. The analysis is a vendor publication that ends by pitching its own UpToDate Connect API.

  • 01The sharper question for any population health or care coordination platform is whether it changes what a clinician does at the moment of decision, or only reports afterward what happened. Wolters Kluwer's reading of the evidence is that many platforms still struggle with the first.
  • 02Vendors selling into value-based contracts now face a build-or-license decision on clinical content, because Wolters Kluwer names current, trusted content, consistent clinician adoption across sites, and a traceable link from guidance to quality metrics as the three hard problems.

Sep 18, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512